A Keker, Van Nest & Peters team – R. James Slaughter, Bailey Heaps, and Ian Kanig – secured a unanimous victory before the Delaware Supreme Court on behalf of Benjamin Cravatt, a world-renowned scientist at Scripps Research and biotechnology entrepreneur. The Court, sitting en banc, affirmed the dismissal of all claims against Cravatt arising from Bayer’s $2 billion acquisition of Vividion Therapeutics, a biotechnology company he co-founded in 2014 that develops targeted cancer therapies.
“Ben Cravatt is an extraordinary scientist whose discoveries have opened new frontiers in medicine and whose companies have created tremendous value. He should be spending his time advancing science, not defending himself against lawsuits brought by a disappointed investor,” said Keker Managing Partner R. James Slaughter. “We’re enormously gratified to have brought these claims to an end, and particularly proud of the outstanding work our team did to achieve that result.”
The lawsuit, brought by an investment entity controlled by venture capitalist John Clarke, alleged that Cravatt and others improperly diverted valuable intellectual property from Vividion in connection with the Bayer acquisition, depriving shareholders of substantial additional merger consideration. The dispute centered on a patent application licensed from Scripps that Vividion relinquished as part of the transaction and that Scripps subsequently licensed to another Cravatt-founded company, Belharra Therapeutics.
In CHP III, L.P. v. Cravatt, the Delaware Supreme Court rejected the investor’s attempt to characterize the alleged loss of corporate intellectual property as a direct injury to shareholders. The Court found that the investor failed to adequately allege that relinquishing the intellectual property reduced the $2 billion acquisition price, particularly because Bayer had agreed to pay the same amount regardless of which intellectual property rights were released. The Court also rejected CHP’s fraud claim. The decision provides guidance on the distinction between direct and derivative shareholder claims under Delaware law.
Partner Laurie Carr Mims and associate Luke Apfeld also assisted the Keker team’s efforts in Delaware Chancery Court.
The ruling marks Keker’s second successful defense of Cravatt against litigation pursued by Clarke. In an earlier lawsuit, Clarke alleged that preliminary discussions about another biotechnology venture had created a binding joint venture. Keker obtained summary judgment for Cravatt and his co-defendants, which the California Court of Appeal affirmed. The Delaware Supreme Court’s decision marks a second appellate victory in two separate cases. The case is CHP III, L.P. v. Cravatt, No. 70, 2026 (Del. Nov. 19, 2026), affirming the dismissal in Delaware Court of Chancery Case No. 2024-0867.